Table 1 Clinical trials for platinum-based chemotherapy in ovarian cancer
From: Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer
Characteristic | Cancer | Treatment regimen | Patients enrolled | PFS(mo) | OS(mo) |
|---|---|---|---|---|---|
Stage III and Stage IV [7] | Ovarian | Cisplatin (75Â mg per square meter of body-surface area) Cyclophosphamide (750Â mg per square meter) | 202 | 13 | 24 |
Cisplatin (75Â mg per square meter of body-surface area) Paclitaxel (135Â mg per square meter over a period of 24Â h). | 184 | 18 | 38 | ||
Stage III and Stage IV [8] (NCT02655016) | Ovarian | Niraparib once daily after a response to platinum-based chemotherapy. | 487 | 13.9 | 84% (24-month interim analysis) |
Placebo group once daily after a response to platinum-based chemotherapy | 246 | 8.2 | 77% (24-month interim analysis) | ||
Relapsed > 6 months following completion of platinum-based therapy [9] (NCT00083122) | Ovarian and Primary Peritoneal Carcinoma | Cisplatin (60 mg/m2 IV) Flavopiridol (100 mg/m2 IV, 24 h infusion; 21 day cycles) | 40 | 4.3 | 16.1 |